The fight against AIDS in the developing world received a boost last week as five pharmaceutical companies joined forces with the United Nations to promote easier access to treatments. Public-health officials welcomed the move, but warned that cheaper drugs alone will not be enough to overcome the HIV epidemic in Africa.
In the same week, US president Bill Clinton issued an Executive Order conceding that African nations can use generic AIDS drugs rather than patented products from US-based companies.
The Joint UN Programme on HIV and AIDS (UNAIDS) and the five drugs companies — Boehringer Ingelheim, Bristol-Myers Squibb, Glaxo Wellcome, Merck and Hoffmann-La Roche — said on 11 May that they had begun a ‘dialogue’ on improving care and treatment for HIV and AIDS in developing countries.
Cheaper drugs will be one key component of the programme. For example, Glaxo Wellcome says it will now provide its anti-HIV combination Combivir (zidovudine and lamivudine), under specific treatment conditions, to developing countries at about $2 per day, instead of the usual $17 per day.
The UN agencies and other international bodies have been trying for at least a decade to get the price of AIDS drugs cut in Africa. To date, more than 80 per cent of all AIDS-related deaths have occurred in this continent. Recent calls to the industry from UN secretary-general Kofi Annan and UN agency heads for partnerships against AIDS appear to have been behind the companies' decision.
Peter Piot, head of UNAIDS, describes the move as “a promising step in a long-term process”. But he warns of the need for “significant new funding” — for example, to ensure that African governments can provide more clinics and trained staff to administer treatment and to monitor patients for the emergence of drug-resistant strains of HIV.
The day before the announcement — and, industry spokespersons insist, entirely coincidentally — President Clinton issued his Executive Order. This prevents the US government from punishing any African government that makes or imports cheap generic AIDS drugs or medical technologies, such as HIV diagnostics, instead of patented products from US-based companies. The order lacks full legal status, but can only be overturned by another Executive Order.
Under the Agreement on Trade-Related Aspects of Intellectual Property Rights, governments can use compulsory licensing to allow the production or sale of products without the permission of the patent holder in exceptional conditions, such as public-health crises.
In the past, when developing countries have tried to use this provision to make or sell cheaper generic AIDS drugs or diagnostics, the US Trade Representative has opposed them, using retaliatory trade tactics or other leverage.
The new Executive Order says that the US government must “refrain from seeking, through negotiation or otherwise, the revocation or revision” of legislation imposed by African governments to get cheaper AIDS drugs to their populations. But African governments must continue to protect US companies' intellectual-property rights.
Senator Dianne Feinstein (Democrat, California), who has been pushing for such a move, welcomed Clinton's decision. In a statement, she said that the order “will give sub-Saharan governments the flexibility to bring life-saving drugs and medical technologies to affected populations while ensuring that fundamental intellectual-property rights are protected”.
But the American pharmaceutical manufacturers' organization, PhRMA, claims compulsory licensing weakens intellectual-property protection and so reduces the incentive for research into new drugs.
Alan Holmer, PhRMA's president, said last week that Clinton's move “sets an undesirable and inappropriate precedent”. PhRMA says it recognizes that AIDS is a major problem, but argues that “weakening intellectual-property rights is not the solution”.
About this article
Towards an early diagnosis of HIV infection: an electrochemical approach for detection ofHIV-1 reverse transcriptase enzyme
The Analyst (2011)
Electrochemical analysis of HIV-1 reverse transcriptase serum level: Exploiting protein binding to a functionalized nanostructured surface
A bioorganometallic approach for rapid electrochemical analysis of human immunodeficiency virus type-1 reverse transcriptase in serum
Electrochimica Acta (2011)
Current Opinion in HIV and AIDS (2007)